tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Inmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline
PremiumRatingsInmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline
2M ago
INmune Bio Reports Q2 2025 Results and Strategic Updates
Premium
Company Announcements
INmune Bio Reports Q2 2025 Results and Strategic Updates
2M ago
INmune Bio CEO RJ Tesi retires, David Moss succeeds
Premium
The Fly
INmune Bio CEO RJ Tesi retires, David Moss succeeds
2M ago
INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
PremiumThe FlyINmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
2M ago
INmune Bio options imply 14.9% move in share price post-earnings
Premium
The Fly
INmune Bio options imply 14.9% move in share price post-earnings
2M ago
INmune Bio Releases Video on Alzheimer’s Trial Results
Premium
Company Announcements
INmune Bio Releases Video on Alzheimer’s Trial Results
3M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
INmune Bio price target lowered to $7 from $20 at Alliance Global Partners
Premium
The Fly
INmune Bio price target lowered to $7 from $20 at Alliance Global Partners
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100